210 related articles for article (PubMed ID: 32779580)
1. Temperature-Dependent Formation of N-Nitrosodimethylamine during the Storage of Ranitidine Reagent Powders and Tablets.
Abe Y; Yamamoto E; Yoshida H; Usui A; Tomita N; Kanno H; Masada S; Yokoo H; Tsuji G; Uchiyama N; Hakamatsuka T; Demizu Y; Izutsu KI; Goda Y; Okuda H
Chem Pharm Bull (Tokyo); 2020 Oct; 68(10):1008-1012. PubMed ID: 32779580
[TBL] [Abstract][Full Text] [Related]
2. N-Nitrosodimethylamine (NDMA) Formation from Ranitidine Impurities: Possible Root Causes of the Presence of NDMA in Ranitidine Hydrochloride.
Yokoo H; Yamamoto E; Masada S; Uchiyama N; Tsuji G; Hakamatsuka T; Demizu Y; Izutsu KI; Goda Y
Chem Pharm Bull (Tokyo); 2021; 69(9):872-876. PubMed ID: 34470951
[TBL] [Abstract][Full Text] [Related]
3. Ranitidine: A Proposed Mechanistic Rationale for NDMA Formation and a Potential Control Strategy.
Harmon P
J Pharm Sci; 2023 May; 112(5):1220-1224. PubMed ID: 36384193
[TBL] [Abstract][Full Text] [Related]
4. N-Nitrosodimethylamine formation in metformin hydrochloride sustained-release tablets: Effects of metformin and hypromellose used in drug product formulation.
Hao G; Hu R; Wang X; Gao P; Wang L; Jiang M; Xin L; Tan G; Zhao Y; Sun F; Chu D; Lv J; You J; Huang F; Song X
J Pharm Biomed Anal; 2023 Jan; 222():115066. PubMed ID: 36191442
[TBL] [Abstract][Full Text] [Related]
5. NDMA Formation Due to Active Ingredient Degradation and Nitrite Traces in Drug Product.
Golob N; Peterlin S; Grahek R; Roškar R
J Pharm Sci; 2023 May; 112(5):1277-1286. PubMed ID: 36925105
[TBL] [Abstract][Full Text] [Related]
6. Characterization of N-nitrosodimethylamine formation from the ozonation of ranitidine.
Lv J; Wang L; Li Y
J Environ Sci (China); 2017 Aug; 58():116-126. PubMed ID: 28774600
[TBL] [Abstract][Full Text] [Related]
7. In Vitro Analysis of N-Nitrosodimethylamine (NDMA) Formation From Ranitidine Under Simulated Gastrointestinal Conditions.
Gao Z; Karfunkle M; Ye W; Marzan TA; Yang J; Lex T; Sommers C; Rodriguez JD; Han X; Florian J; Strauss DG; Keire DA
JAMA Netw Open; 2021 Jun; 4(6):e2118253. PubMed ID: 34181009
[TBL] [Abstract][Full Text] [Related]
8. Oral intake of ranitidine increases urinary excretion of N-nitrosodimethylamine.
Zeng T; Mitch WA
Carcinogenesis; 2016 Jun; 37(6):625-634. PubMed ID: 26992900
[TBL] [Abstract][Full Text] [Related]
9. A Bioanalytical Method for Quantification of N-nitrosodimethylamine (NDMA) in Human Plasma and Urine with Different Meals and following Administration of Ranitidine.
De Palma R; Patel V; Florian J; Keire D; Selaya D; Strauss DG; Rouse R; Matta MK
J Pharm Sci; 2023 May; 112(5):1315-1323. PubMed ID: 36736776
[TBL] [Abstract][Full Text] [Related]
10.
Zmysłowski A; Książek I; Szterk A
Molecules; 2020 Nov; 25(22):. PubMed ID: 33202951
[TBL] [Abstract][Full Text] [Related]
11. HS-SPME-GC-MS as an alternative method for NDMA analysis in ranitidine products.
Alshehri YM; Alghamdi TS; Aldawsari FS
J Pharm Biomed Anal; 2020 Nov; 191():113582. PubMed ID: 32889348
[TBL] [Abstract][Full Text] [Related]
12. Reduction of N-nitrosodimethylamine formation from ranitidine by ozonation preceding chloramination: influencing factors and mechanisms.
Zou R; Liao X; Zhao L; Yuan B
Environ Sci Pollut Res Int; 2018 May; 25(14):13489-13498. PubMed ID: 29492817
[TBL] [Abstract][Full Text] [Related]
13. Investigating the root cause of N-nitrosodimethylamine formation in metformin pharmaceutical products.
Nasr NEH; Metwaly MG; Ahmed EO; Fares AR; ElMeshad AN
Expert Opin Drug Saf; 2021 Jul; 20(7):855-862. PubMed ID: 33849366
[TBL] [Abstract][Full Text] [Related]
14. Bumetanide as a Model NDSRI Substrate: N-nitrosobumetanide Impurity Formation and its Inhibition in Bumetanide Tablets.
Shakleya D; Asmelash B; Alayoubi A; Abrigo N; Mohammad A; Wang J; Zhang J; Yang J; Marzan TA; Li D; Shaklah M; Alsharif FM; Desai S; Faustino PJ; Ashraf M; O'Connor T; Vera M; Raw A; Sayeed VA; Keire D
J Pharm Sci; 2023 Dec; 112(12):3075-3087. PubMed ID: 37364772
[TBL] [Abstract][Full Text] [Related]
15. Avoiding N-nitrosodimethylamine formation in metformin pharmaceuticals by limiting dimethylamine and nitrite.
Schlingemann J; Boucley C; Hickert S; Bourasseau L; Walker M; Celdran C; Chemarin T; Pegues C; Fritzsche M; Keitel J; Goettsche A; Seegel M; Leicht S; Guessregen B; Reifenberg P; Wetzel S; Müller T; Schooren F; Schuster T; Liebhold M; Kirsch A; Krueger P; Saal C; Mouton B; Masanes S
Int J Pharm; 2022 May; 620():121740. PubMed ID: 35421534
[TBL] [Abstract][Full Text] [Related]
16. Patient In-Use Stability Testing of FDA-Approved Metformin Combination Products for N-Nitrosamine Impurity.
Dharani S; Mohamed EM; Rahman Z; Khan MA
AAPS PharmSciTech; 2024 Jan; 25(1):19. PubMed ID: 38267707
[TBL] [Abstract][Full Text] [Related]
17. Isolation of N-nitrosodimethylamine from drug substances using solid-phase extraction-liquid chromatography-tandem mass spectrometry.
Yamamoto E; Kan-No H; Tomita N; Ando D; Miyazaki T; Izutsu KI
J Pharm Biomed Anal; 2022 Feb; 210():114561. PubMed ID: 34974238
[TBL] [Abstract][Full Text] [Related]
18. Chloramination of nitrogenous contaminants (pharmaceuticals and pesticides): NDMA and halogenated DBPs formation.
Le Roux J; Gallard H; Croué JP
Water Res; 2011 May; 45(10):3164-74. PubMed ID: 21496861
[TBL] [Abstract][Full Text] [Related]
19. Application of an optimized total N-nitrosamine (TONO) assay to pools: placing N-nitrosodimethylamine (NDMA) determinations into perspective.
Kulshrestha P; McKinstry KC; Fernandez BO; Feelisch M; Mitch WA
Environ Sci Technol; 2010 May; 44(9):3369-75. PubMed ID: 20355696
[TBL] [Abstract][Full Text] [Related]
20. Determination of
Liu J; Zhao Z; Yang X; Jin Y; Liu X; Wang C; Zhang Z
Iran J Pharm Res; 2021; 20(4):255-264. PubMed ID: 35194444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
